Belpointe Asset Management »

Esperion Therapeutics shares owned by Belpointe Asset Management

Quarter-by-quarter ownership of Esperion Therapeutics (ESPR) shares owned by Belpointe Asset Management from 13F filings

Historical chart of Belpointe Asset Management investment in Esperion Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Esperion Therapeutics held by Belpointe Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Esperion Therapeutics by Belpointe Asset Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $126k 47k 2.68

More positions owned by Belpointe Asset Management

Apple (AAPL)
Spdr S&p 500 Etf Trust Etf (SPY)
Invesco Qqq Tr Unit Ser 1 Etf (QQQ)
NVIDIA Corporation (NVDA)
Microsoft Corporation (MSFT)
Vanguard S&p 500 Etf Etf (VOO)
Badger Meter (BMI)
Collaborative Investmnt Ser Etf (RSEE)
Amazon (AMZN)
Berkshire Hathaway (BRK.B)
Spdr Ser Tr Etf (SPLG)
Belpointe Prep Etf (OZ)
Facebook Inc cl a (META)
Ishares Tr Etf (IVV)
Spdr Series Trust Spdr Bloomberg 1 3 Month T Bill Etf Etf (BIL)

View all positions for Belpointe Asset Management

Top funds holding Esperion Therapeutics

OrbiMed Advisors
Bellevue Group
Daniel D. Thurber
Vanguard Group
Dr. Jeffrey R. Jay, M.D.
Woodline Partners
Millennium Management
D. E. Shaw & Co
Bank of America Corporation
Two Seas Capital
Two Sigma Investments
Meditor
Citadel Advisors
Two Sigma Advisers
Goldman Sachs Group

View all funds holding Esperion Therapeutics